Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Genzyme Canada, a biotechnology and healthcare products company, has launched Synvisc-One, a single injection viscosupplement approved for osteoarthritis of the knee. The company has earlier received Health Canada approval for Synvisc-One injection.
Subscribe to our email newsletter
According to Genzyme Canada, Synvisc-One is the latest addition to its Synvisc family of products used to treat osteoarthritis including: a single 2ml injection for the hip, shoulder and ankle, and a 3 X 2ml dosage format for the knee.
Synvisc-One has been shown to significantly improve osteoarthritis knee pain for up to six months with a low incidence of local side effects, the company said.
Brian Lewis, general manager of Genzyme Canada, said: “For Canadians with osteoarthritis, the availability of Synvisc-One provides a convenient option with proven effectiveness for those suffering needlessly from knee pain.”